Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Updates in ALK+ NSCLC

Ross Camidge, MD, PhD, University of Colorado Aurora, Colorado, USA, discusses updates in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and his thoughts on interpreting the data from clinical trials to better treat patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).